Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
BlossomHill Therapeutics (BLSM): Analyst Targets Suggest Potential +156% Upside to $35

BlossomHill Therapeutics (BLSM): Analyst Targets Suggest Potential +156% Upside to $35

Key Takeaways

  • The central target of $35 is the arithmetic mean of five verified analyst price targets, rounded from $35.40.
  • The verified individual targets range from $30 to $40, with every analyst rating BLSM a Buy or equivalent.
  • At a recent price of $13.65, reaching $35 would require roughly a 156% advance — a very large move.
  • The strongest support is the clinical potential of lead asset BH-30643 in EGFR-mutant non-small cell lung cancer (NSCLC), the core of most analyst theses.
  • The biggest risks are BLSM's pre-revenue status, ongoing cash burn, and the binary, data-dependent nature of oncology development.
  • For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
  • To see how AI-driven strategies track opportunities across the market, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Five current, verifiable analyst price targets form the basis of this analysis. The individual targets are: J.P. Morgan at $30, LifeSci Capital at $32, H.C. Wainwright at $35, Guggenheim at $40, and Leerink Partners at $40. The range spans $30 to $40, and the arithmetic mean of these five figures is $35.40, which rounds to a clean central target of $35.

Every covering analyst rates the stock a Buy or Outperform, but their estimates reflect meaningfully different assumptions about the probability of clinical success. Guggenheim and Leerink sit at the top of the range. Guggenheim raised its target to $40 from $30 in September 2026, citing higher odds-of-success assumptions for BH-30643 in first-line EGFR-mutant NSCLC following durability data presented at the World Conference on Lung Cancer (WCLC). Leerink also lifted its target to $40 from $36. J.P. Morgan's more conservative $30 target and LifeSci Capital's $32 reflect greater caution about execution and clinical timelines. The mean is a summary, not a guarantee, and the wide range underscores how much uncertainty surrounds a pre-revenue biotech. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

BLSM last traded near $13.65, with a market capitalization of roughly $434 million and a 52-week range of $11.02 to $27.99. Reaching $35 from $13.65 would require an advance of about 156% — a very large move that would also carry the shares well above their prior 52-week high.

The company does not yet generate product revenue; EPS (earnings per share) over the trailing twelve months is negative. The path toward a higher price therefore runs almost entirely through clinical data. Each positive readout on BH-30643 or other pipeline candidates has the potential to re-rate the shares, while any setback would likely pressure the stock, as the sharp intraday swings around its November 2026 earnings report illustrate.

What Could Support a Move Toward the Target

  • Lead asset BH-30643: Analysts view this candidate as the primary near-term value driver, particularly in the C797S-EGFR mutation setting and first-line EGFR-mutant NSCLC, where durability data has encouraged bullish target revisions.
  • Precision oncology pipeline: Guggenheim framed the pipeline's potential for "significant upside," pointing to multiple shots on goal in oncology.
  • Analyst alignment: A unanimous Buy consensus and several recent upward target revisions indicate improving sentiment rather than downgrade pressure.
  • Balance sheet: With roughly $225 million in cash, the company has funding to advance clinical programs without an immediate need to raise capital.

What Could Prevent the Target From Being Reached

  • Clinical risk: A failed or inconclusive trial readout could sharply reduce the probability-weighted value of the pipeline and trigger target cuts.
  • No current revenue: BLSM's valuation rests on future approvals, leaving the stock exposed to sentiment shifts and biotech sector rotation.
  • Cash burn: As a clinical-stage company, continued operating losses may eventually require additional financing, which could dilute existing holders.
  • Competition and regulation: The EGFR-mutant NSCLC field is crowded, and regulatory or clinical setbacks elsewhere could weigh on the broader oncology group.

Technical Levels and Market Structure

The stock IPO'd in August 2026 and reached a 52-week high of $27.99 in September before pulling back sharply. The 52-week low of $11.02, set in early November 2026, marks a key support level to watch. BLSM currently trades below its 50-day moving average, indicating near-term downward pressure. On the upside, a prior consolidation zone around $16 to $18 represents the first meaningful resistance, followed by the $27.99 record high. Because the $35 target sits above that all-time high, the stock would need to establish new highs through sustained positive clinical catalysts.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms apply their own assumptions. Investors focused on the $35 target should monitor upcoming BH-30643 data readouts, management guidance on development timelines, any analyst target revisions, and quarterly cash-position updates. Biotech sentiment, interest-rate expectations, and broader sector flows can also influence how richly the market values pre-revenue oncology names. None of these factors provides a definitive timing signal. From what I see, reviewing these elements with tools like Tickeron’s AI Trend Prediction Engine helps clarify the probabilities involved.

Using AI for Biotech Opportunity Tracking

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, data-driven name like BLSM, this kind of automated surveillance can help traders spot shifting trends and momentum more efficiently than manual chart review. The tool is designed to support opportunity discovery, position monitoring, and trend identification across a broad universe of securities. In my experience, integrating it into routine analysis provides an additional layer of perspective on names like this one.

Final Assessment

The $35 central target is an analyst-derived average — the mean of five verified targets ranging from $30 to $40 — not a forecast of what will happen. From a price near $13.65, the required move of roughly 156% is very large and would take the stock beyond its prior record high. The strongest support comes from the clinical potential of BH-30643 and a unanimously bullish analyst consensus, while the principal obstacles are BLSM's pre-revenue status, ongoing cash burn, and the inherent binary risk of oncology development. The wide spread between the lowest and highest targets reflects genuine disagreement about clinical probability. Investors should watch upcoming data readouts, analyst revisions, and the company's cash position, while recognizing that a $35 outcome is possible, not assured.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BLSM

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
10255 Science Center Drive
Phone
+1 858 732-3880
Employees
63
Web
https://www.bhtherapeutics.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.